Literature DB >> 28348098

Response by Yang and Gu to Letter Regarding Article, "Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China)".

Xueli Yang1, Dongfeng Gu1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28348098     DOI： 10.1161/CIRCULATIONAHA.117.027318

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  4 in total

1.  Chronic infusion of ELABELA alleviates vascular remodeling in spontaneously hypertensive rats via anti-inflammatory, anti-oxidative and anti-proliferative effects.

Authors:  Chao Ye; Zhi Geng; Ling-Li Zhang; Fen Zheng; Ye-Bo Zhou; Guo-Qing Zhu; Xiao-Qing Xiong
Journal:  Acta Pharmacol Sin       Date:  2022-03-08       Impact factor: 7.169

2.  ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway.

Authors:  Zhida Chen; Chunying Wu; Yuting Liu; Haonan Li; Yeyan Zhu; Cailing Huang; Huangbo Lin; Qiao Qiao; Mengming Huang; Qing Zhu; Lei Wang
Journal:  Cell Death Dis       Date:  2020-08-22       Impact factor: 8.469

3.  Using Multiple Statistical Methods to Derive Dietary Patterns Associated with Cardiovascular Disease in Patients with Type 2 Diabetes: Results from a Multiethnic Population-Based Study.

Authors:  Tingting Qiao; Hui Zhao; Tao Luo; Duolao Wang; Kaili Mu; Aliya Aimudula; Hualian Pei; Guozhen Zhang; Jianghong Dai
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-09       Impact factor: 2.650

4.  Vasoactive Drug Therapy and Clinical Nursing of Patients with Cardiovascular Disease.

Authors:  Menglin Li; Meixiang Xu; Minfang Feng; Lingyan Ren
Journal:  Contrast Media Mol Imaging       Date:  2022-09-21       Impact factor: 3.009
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.